Prosecution Insights
Last updated: April 19, 2026
Application No. 17/909,589

2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS

Non-Final OA §102
Filed
Sep 06, 2022
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Om Pharma SA
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election of Group I, and species of IIc-007a, in the reply filed on June 16, 2025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). 3. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be novel and nonobvious over the prior art. Therefore, the search and examination was extended. Prior art was found that anticipates the Markush claims with respect to nonelected species. The Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species, the full scope of claims 21 and 23 and additionally to the extent of the nonelected species shown in this office action. 4. Claims 18-20, 22 and 24-32 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter. Election was made without traverse in the reply filed on June 16, 2025. Priority 5. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement 6. The information disclosure statements (dated January 14, 2025 and March 9, 2023) were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 1449 are enclosed herewith. Claim Objections 7. Claims 21 and 23 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 8. Claim(s) 16, 17 and 33 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2604445-65-8 ( PNG media_image1.png 142 326 media_image1.png Greyscale ). The reference has a date of March 5, 2021 which antedates the present claims having an effective filing date of March 8, 2021. Priority claim to foreign application dated March 11, 2020 is noted. However, the priority date cannot be granted because the present claims are not sufficiently supported by the foreign document under 35 USC 112. The reference corresponds to the present claims in the following manner: Ra=Rb=H; R1=COO(R4=H); R2=H; R3=R5=R7 substituted with O(R4=H). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 06, 2022
Application Filed
Aug 01, 2025
Non-Final Rejection — §102
Aug 26, 2025
Response Filed
Aug 26, 2025
Response after Non-Final Action
Feb 06, 2026
Applicant Interview (Telephonic)
Feb 06, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month